Merck & Co., Inc.
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 14, 2025), Merck & Co., Inc. reported 12 stock positions worth $164.3 million. Its top holding was Moderna (MRNA) at 39.8% of the portfolio, followed by Personalis (PSNL, 30.0%) and Kymera Therapeutics (KYMR, 12.9%). Compared with Q4 2024, it sold out of 1 and added to 1. The biggest buy was Evaxion Biotech A/S (EVAX, shares +124%) and the biggest sale an exit from Absci (ABSI).
- Most Recent 13F
- Q2 2026
- Location
- RAHWAY, NJ
- CIK
- 0000310158
- Portfolio Value
- $164.3M (Q1 2025)
- SEC Filing
- 0000064978-25-000005 ↗ filed May 14, 2025
Holdings Value
Holdings 12 stocks · $164.3M
| MRNA Moderna Inc. | 39.83% | 2,308,190 | $65.4M | No change |
| PSNL Personalis Inc. | 30.01% | 14,044,943 | $49.3M | No change |
| KYMR Kymera Therapeutics Inc. | 12.86% | 772,165 | $21.1M | No change |
| ENTRADA THERAPEUTICS INC | 9.57% | 1,739,768 | $15.7M | No change |
| ALEC Alector Inc. | 2.65% | 3,545,719 | $4.4M | No change |
| EVAX Evaxion Biotech A/S | 1.37% | 1,214,126 | $2.2M | Add +123.9% |
| STRO Sutro Biopharma Inc. Com SHS | 1.08% | 2,723,509 | $1.8M | No change |
| LVTX Lava Therapeutics NV | 0.89% | 1,149,345 | $1.5M | No change |
| VRDN Viridian Therapeutics Inc. | 0.77% | 93,414 | $1.3M | No change |
| XLO Xilio Therapeutics Inc. | 0.65% | 1,483,758 | $1.1M | No change |
| CARM Carisma Therapeutics Inc. | 0.28% | 1,473,240 | $457K | No change |
| NEUP Neuphoria Therapeutics Inc. | 0.04% | 10,027 | $58K | No change |
Portfolio Sells Q4 2024 → Q1 2025
| ABSI Absci Corp. | Sold out | 0.00% | −1.01 |
Portfolio Buys Q4 2024 → Q1 2025
| EVAX Evaxion Biotech A/S | Add +123.9% | 1.37% | +1.19 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 13 | $526.4M | PSNL, MRNA, KYMR, AKTS, EIKN |
| Q1 2026 | 14 | $349.4M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, EIKN |
| Q4 2025 | 12 | $276.3M | PSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, EVAX |
| Q3 2025 | 13 | $228.0M | PSNL, MRNA, KYMR, ALEC, ENTRADA THERAPEUTICS INC |
| Q2 2025 | 13 | $215.6M | PSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, ALEC |
| Q1 2025 | 12 | $164.3M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC |
| Q4 2024 | 13 | $258.0M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC |